Cargando…

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary objective of AMP utilizes sieve analysis to investigate how VRC01 prevention efficacy (PE) varies with HIV-1 envelope (Env) amin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magaret, Craig A., Benkeser, David C., Williamson, Brian D., Borate, Bhavesh R., Carpp, Lindsay N., Georgiev, Ivelin S., Setliff, Ian, Dingens, Adam S., Simon, Noah, Carone, Marco, Simpkins, Christopher, Montefiori, David, Alter, Galit, Yu, Wen-Han, Juraska, Michal, Edlefsen, Paul T., Karuna, Shelly, Mgodi, Nyaradzo M., Edugupanti, Srilatha, Gilbert, Peter B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459550/ https://www.ncbi.nlm.nih.gov/pubmed/30933973 http://dx.doi.org/10.1371/journal.pcbi.1006952

Ejemplares similares

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals
por: Edupuganti, Srilatha, et al.
Publicado: (2019)

Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research
por: Williamson, Brian D., et al.
Publicado: (2023)

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Partial germline reversions can increase VRC07 potency and breadth
por: Rudicell, RS, et al.
Publicado: (2012)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
por: Knudsen, Maria L., et al.
Publicado: (2022)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
por: Theodore, Deborah, et al.
Publicado: (2023)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection
por: Cortez, Valerie, et al.
Publicado: (2015)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
por: Caniels, Tom G., et al.
Publicado: (2023)

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe
por: Murombedzi, Caroline, et al.
Publicado: (2023)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

BBBBB160 /
por: Kozer, José
Publicado: (2013)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

Sequence and functional characterization of a public HIV-specific antibody clonotype
por: Murji, Amyn A., et al.
Publicado: (2021)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

Making your geriatric and palliative programs a strength: TQIP guideline implementation and the VRC perspective
por: Ho, Vanessa P, et al.
Publicado: (2021)

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
por: Gray, Matthew D., et al.
Publicado: (2022)

Doubly robust nonparametric inference on the average treatment effect
por: Benkeser, D, et al.
Publicado: (2017)

Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
por: Fong, Youyi, et al.
Publicado: (2023)

Nucleoporin 160 (NUP160) inhibition alleviates diabetic nephropathy by activating autophagy
por: Xie, Jiayong, et al.
Publicado: (2021)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy
por: Gilbert, Peter B, et al.
Publicado: (2019)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

Advancing the use of Long‐Acting Extended Delivery formulations for HIV prevention in sub‐Saharan Africa: challenges, opportunities, and recommendations
por: Mgodi, Nyaradzo M., et al.
Publicado: (2023)

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
por: Donnell, Deborah, et al.
Publicado: (2023)

Optics and lasers: with 160 figures
por: Young, Matt
Publicado: (1984)

160th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2002)

Experiment S160 - progress report
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_as0jk4btnthtm5gha361hhtp3l